Nami Surgical raises £3.4 million for robotic surgery tools

Glasgow medtech firm Nami Surgical has raised £3.4 million in a funding round extension to support the development and commercialisation of its ultrasonic tools for robotic surgery, according to Surgical Robotics Technology.

The Scottish National Investment Bank led the extension with a £2 million investment. Additional funding came from existing investors including Eos Advisory, Scottish Enterprise, and the Investment Fund for Scotland, which is managed by Maven Capital Partners and delivered by the British Business Bank. Eos Advisory previously led Nami Surgical's prior two funding rounds.

Founded in 2021 as a University of Glasgow spin-out by Dr Nico Fenu and Dr Rebecca Cleary, Nami Surgical developed a patent-protected miniaturised ultrasonic scalpel. The company designed its instruments to overcome physical limitations found in conventional surgical devices.

Ultrasonic Technology

Ultrasonic scalpels cut tissue and seal blood vessels simultaneously using high-frequency vibrations. Existing ultrasonic instruments have traditionally been too large and rigid for robotic surgical devices to use effectively.

Nami Surgical addresses this limitation by miniaturising the transducer, the core component that produces ultrasonic vibration. The smaller transducer allows the surgical tool to bend and rotate inside robotic systems without losing its tissue-cutting and vessel-sealing capabilities.

The company will use the new capital to expand its research and development operations and support commercial efforts. The expansion will add five engineering jobs at its headquarters in Hillington, in southwest Glasgow.

Commercial Expansion

The investment follows several operational milestones achieved by the business in 2026. Nami Surgical received ISO 13485 certification, which sets international safety and quality standards for medical devices, and won Bio-tech Manufacturer of the Year at the 2026 Made in Scotland Awards.

The firm also expanded its executive leadership team earlier in the year, appointing Nikki Palfrey as chief executive officer in January 2026.

"We have reached an important stage in Nami’s development, moving from demonstrating the potential of our technology to building the capabilities and partnerships needed to bring it into the surgical environment," Palfrey said.

"This investment gives us the resources to accelerate that journey, strengthening our engineering team in Glasgow while continuing to generate the evidence and relationships required for commercial adoption," Palfrey added.

Nami Surgical is now seeking strategic partnerships with global healthcare companies to expand adoption of its instruments in robotic-assisted procedures.